IL6 and neoplasm: For example, trials of IL-6 or IL-6 receptor antibodies (clazakizumab and tocilizumab) in gastrointestinal cancers have shown reduced IL-6 levels, inhibited muscle loss, and improved albumin levels without accelerating tumor growth [255].